Altogether, STINGel demonstrates its indirect antinociceptive impact by reducing the tumor burden through enhancing the presence of M1-like macrophages and N1-like neutrophils and concurrently activating immune response pathways through the upregulation of TNF and MIF signaling pathways. The gene discussed is MIF; the disease is neoplasm.